Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA TherapeuticsA new wave of innovation is taking hold across the biotech and tech sectors, with four high-impact companies— Peraso Inc. (
NASDAQ: PRSO), Lexicon Pharmaceuticals (
NASDAQ: LXRX), Portage Biotech (
NASDAQ: PRTG), and TransCode Therapeutics (
NASDAQ: RNAZ) —each making strategic advances in their respective arenas: military-grade wireless, obesity treatment, cancer immunotherapy, and RNA-based oncology solutions. These breakthroughs represent critical inflection points for investors eyeing cutting-edge solutions backed by scientific validation, regulatory momentum, and untapped market potential.
“Stocks Under $1 Gaining Momentum: WBUY, KAVL, OMEX, PRTG, RJDG – Driving Innovation, Market Trends, and Growth Potential”Stocks priced under $1 provide an affordable entry for investors aiming for high potential returns. These five emerging companies show strong growth potential, and with market trends favoring undervalued sectors, they are worth considering now.
Portage Biotech CEO Interview Explains Why His Company Can Be Poised To Break Higher In 2H 2021 (NASDAQ: PRTG)A bullish interview by Portage Biotech (NasdaqCM: PRTG) CEO Ian Walters sets the stage for a return trip back to its YTD highs of $44.98, representing a more than 100% gain from current levels. In fact, everything he said supports the narrative that its current share price is far less indicative of what's happening in the clinic. In fact, with multiple shots on goal, its current share price hardly represents PRTG's industry experience, leadership, and clinical pipeline at all. The excellent news is that with near-term catalysts expected, its valuation gap should close.
Portage Biotech Added to Russell 2000(R) IndexWestport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (
NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology...
Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary SharesWestport, Connecticut--(Newsfile Corp. - June 24, 2021) - Portage Biotech Inc. (
NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology...
Portage Biotech Inc. Announces Proposed Offering of Ordinary SharesWestport, Connecticut--(Newsfile Corp. - June 23, 2021) - Portage Biotech Inc. (
NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology...
Portage Biotech Announces Voluntary Delisting from the Canadian Securities ExchangeWestport, Connecticut--(Newsfile Corp. - April 16, 2021) - Portage Biotech Inc., (
NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a...
